USA - New York Stock Exchange - NYSE:NVTA - US46185L1035 - Common Stock
The current stock price of NVTA is 0.0891 USD. In the past month the price decreased by -82.72%. In the past year, price decreased by -95.72%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.04 | 96.01B | ||
| CI | THE CIGNA GROUP | 9.34 | 70.91B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 118.23 | 21.75B | ||
| LH | LABCORP HOLDINGS INC | 16.33 | 21.42B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.7 | 20.30B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.14B | ||
| HIMS | HIMS & HERS HEALTH INC | 72.59 | 8.92B | ||
| DVA | DAVITA INC | 12.72 | 8.29B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 35.09 | 6.45B | ||
| RDNT | RADNET INC | 206.82 | 6.06B | ||
| CHE | CHEMED CORP | 19.18 | 5.98B | ||
| OPCH | OPTION CARE HEALTH INC | 20.06 | 4.74B |
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. The company is headquartered in San Francisco, California and currently employs 1,700 full-time employees. The company went IPO on 2015-02-12. The firm is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. The company offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. The company applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The firm also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The firm has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.
INVITAE CORP
1400 16Th Street
San Francisco CALIFORNIA 94103 US
CEO: Sean E. George
Employees: 1700
Phone: 14153747782
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. The company is headquartered in San Francisco, California and currently employs 1,700 full-time employees. The company went IPO on 2015-02-12. The firm is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. The company offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. The company applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The firm also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The firm has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.
The current stock price of NVTA is 0.0891 USD. The price decreased by -77.12% in the last trading session.
NVTA does not pay a dividend.
NVTA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
INVITAE CORP (NVTA) currently has 1700 employees.
INVITAE CORP (NVTA) has a market capitalization of 25.53M USD. This makes NVTA a Nano Cap stock.
You can find the ownership structure of INVITAE CORP (NVTA) on the Ownership tab.
ChartMill assigns a fundamental rating of 2 / 10 to NVTA. Both the profitability and financial health of NVTA have multiple concerns.
Over the last trailing twelve months NVTA reported a non-GAAP Earnings per Share(EPS) of -1.11. The EPS increased by 58.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -269.22% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
13 analysts have analysed NVTA and the average price target is 0.72 USD. This implies a price increase of 712.79% is expected in the next year compared to the current price of 0.0891.
For the next year, analysts expect an EPS growth of 53.25% and a revenue growth -6.03% for NVTA